ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
Saved in:
| Title: | ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. |
|---|---|
| Authors: | Lozinski M; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia., Bowden NA; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia., Graves MC; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia., Fay M; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.; GenesisCare, Newcastle, NSW, Australia., Day BW; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Stringer BW; Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia., Tooney PA; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia. |
| Source: | Oncotarget [Oncotarget] 2024 Jan 16; Vol. 15, pp. 1-18. Date of Electronic Publication: 2024 Jan 16. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
